BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387:2008-2016. [PMID: 26969090 DOI: 10.1016/s0140-6736(16)00559-6] [Cited by in Crossref: 385] [Cited by in F6Publishing: 426] [Article Influence: 64.2] [Reference Citation Analysis]
Number Citing Articles
1 Xie R, Wu J, Shang B, Bi X, Jiang W, Cao C, Zhou A, Shi H, Shou J. Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta‐analysis of safety. Cancer Medicine 2022. [DOI: 10.1002/cam4.5504] [Reference Citation Analysis]
2 Hilser T, Kuczyk M, Darr C, Grünwald V. Aktuelle Konzepte für die perioperative Systemtherapie beim fortgeschrittenen Nierenzellkarzinom. Urologie 2022. [DOI: 10.1007/s00120-022-01970-w] [Reference Citation Analysis]
3 Patel N, Hakansson A, Ohtake S, Muraki P, Proudfout JA, Liu Y, Webber L, Ibarra A, Liu VYT, Davicioni E, Chamie K, Pantuck A, Shuch B. Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate‐risk clear cell kidney cancer. Cancer Medicine 2022. [DOI: 10.1002/cam4.5399] [Reference Citation Analysis]
4 Fitzgerald KN, Motzer RJ, Lee C. Adjuvant therapy options in renal cell carcinoma — targeting the metastatic cascade. Nat Rev Urol 2022. [DOI: 10.1038/s41585-022-00666-2] [Reference Citation Analysis]
5 Wang Z, Tian X, Wang Y, Wang J, Ye S, Huang Y, Qu Y, Chang K, Shi G, Ye D, Gu C. The expression and prognostic value of transporter 1, ATP binding cassette subfamily B member in clear cell renal cell cancer with experimental validation. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1013790] [Reference Citation Analysis]
6 Bigot P, Barthelemy P, Boissier R, Khene Z, Pettenati C, Bernhard J, Correas J, Doumerc N, Gimel P, Ingels A, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Albiges L, Rouprêt M. French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer. Progrès en Urologie 2022;32:1195-1274. [DOI: 10.1016/j.purol.2022.07.146] [Reference Citation Analysis]
7 Heymach JV, Zurita‐saavedra A, Kopetz S, Cascone T, Nilsson M, Guijarro I. Tumor Angiogenesis. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm017.pub2] [Reference Citation Analysis]
8 Grigg CM, Burgess EF, Riggs SB, Zhu J, Raghavan D. Renal Cell Carcinoma. Holland‐Frei Cancer Medicine 2022. [DOI: 10.1002/9781119000822.hfcm097.pub2] [Reference Citation Analysis]
9 Bottiglieri A, Sepe P, Stellato M, Pircher C, Fotia G, Leone AG, Guadalupi V, Claps M, Giannatempo P, Verzoni E, Procopio G. Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Following Nephrectomy. Cancer Manag Res 2022;14:3071-81. [PMID: 36275783 DOI: 10.2147/CMAR.S360441] [Reference Citation Analysis]
10 Lee HW, Seo HS, Yeom S, Kim S, Kim CR, Park D, Park W, Choy YB, Park CG, Seo SI. Cabozantinib-Loaded PLGA Nanoparticles: A Potential Adjuvant Strategy for Surgically Resected High-Risk Non-Metastatic Renal Cell Carcinoma. IJMS 2022;23:12634. [DOI: 10.3390/ijms232012634] [Reference Citation Analysis]
11 Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. The Lancet 2022;400:1103-16. [DOI: 10.1016/s0140-6736(22)01658-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
12 Renner A, Rojas C, Walton-diaz A, Burotto M. Adjuvant therapy for renal cell carcinoma, finally a new standard? Front Oncol 2022;12:926661. [DOI: 10.3389/fonc.2022.926661] [Reference Citation Analysis]
13 Zuo Y, Fu S, Zhao Z, Li Z, Wu Y, Qi T, Zheng J, Du Q, Xu Z, Yu N. Sarcomatoid-associated gene risk index for clear cell renal cell carcinoma. Front Genet 2022;13:985641. [DOI: 10.3389/fgene.2022.985641] [Reference Citation Analysis]
14 Kotlyar M, Krebs M, Burger M, Kübler H, Bargou R, Kneitz S, Otto W, Breyer J, Vergho DC, Kneitz B, Kalogirou C. Evaluation of a microRNA-based Risk Classifier Predicting Cancer-Specific Survival in Renal Cell Carcinoma with Tumor Thrombus of the Inferior Vena Cava.. [DOI: 10.1101/2022.09.03.22279559] [Reference Citation Analysis]
15 Bedke J. Adjuvante Therapie beim Nierenzellkarzinom. Uro-News 2022;26:26-31. [DOI: 10.1007/s00092-022-4974-2] [Reference Citation Analysis]
16 Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang Y, Lee JL, Sarwar N, Thiery-vuillemin A, Gross-goupil M, Mahave M, Haas NB, Sawrycki P, Burgents JE, Xu L, Imai K, Quinn DI, Choueiri TK, Tomczak P, Choueiri T, Park SH, Venugopal B, Ferguson TR, Hajek J, Lin T, Symeonides SN, Lee JL, Sawrycki P, Haas NB, Gurney HP, Mahave M, Sarwar N, Thiery-vuillemin A, Gross-goupil M, Chevreau C, Burke JM, Doshi G, Melichar B, Topart D, Oudard S, Kopyltsov E, Hammers H, Quinn DI, Alva A, Menezes JDJ, Silva AGE, Winquist EW, Hamzaj A, Procopio G, Karaszewska B, Nowakowska-zajdel EM, Alekseev BY, Gafanov RA, Izmailov A, Semenov A, Afanasyev SG, Lipatov ON, Powles TB, Srinivas S, Mcdermott D, Kochuparambil ST, Davis ID, Peltola K, Sabbatini R, Chung J, Shkolnik MI, Matveev VB, Gajate Borau P, Mccune S, Hutson TE, Dri A, Sales SC, Yeung C, Alcala Castro CM, Bostrom P, Laguerre B, Buttigliero C, de Giorgi U, Fomin EA, Zakharia Y, Hwang C, Singer EA, Yorio JT, Waterhouse D, Kowalyszyn RD, Alfie MS, Yanez Ruiz E, Buchler T, Kankaanranta K, Ferretti G, Kimura G, Nishimura K, Masumori N, Tamada S, Kato H, Kitamura H, Danielewicz I, Wojcik-tomaszewska J, Sala Gonzalez N, Chiu K, Atkins MB, Heath E, Rojas-uribe GA, Gonzalez Fernandez ME, Feyerabend S, Pignata S, Numakura K, Cybulska Stopa B, Zukov R, Climent Duran MA, Maroto Rey PJ, Montesa Pino A, Chang C, Vengalil S, Waddell TS, Cobb PW, Hauke R, Anderson DM, Sarantopoulos J, Gourdin T, Zhang T, Jayram G, Fein LE, Harris C, Beato PMM, Flores F, Estay A, Rubiano JA, Bedke J, Hauser S, Neisius A, Busch J, Anai S, Tsunemori H, Sawka D, Sikora-kupis B, Arranz JA, Delgado I, Chen C, Gunderson E, Tykodi S, Koletsky A, Chen K, Agrawal M, Kaen DL, Sade JP, Tatangelo MD, Parnis F, Barbosa FM, Faucher G, Iqbal N, Marceau D, Paradis J, Hanna N, Acevedo A, Ibanez C, Villanueva L, Galaz PP, Durango IC, Manneh R, Kral Z-, Holeckova P, Hakkarainen H, Ronkainen H, Abadie-lacourtoisie S, Tartas S, Goebell PJ, Grimm M, Hoefner T, Wirth M, Panic A, Schultze-seemann W, Yokomizo A, Mizuno R, Uemura H, Eto M, Tsujihata M, Matsukawa Y, Murakami Y, Kim M, Hamberg P, Marczewska-skrodzka M, Szczylik C, Humphreys AC, Jiang P, Kumar B, Lu G, Desai A, Karam JA, Keogh G, Fleming M, Zarba JJ, Leiva VE, Mendez GA, Harris SJ, Brown SJ, Antonio Junior JN, Costamilan RDC, Rocha RO, Muniz D, Brust L, Lalani A, Graham J, Levesque M, Orlandi F, Kotasek R, Deville JL, Borchiellini D, Merseburger A, Rink M, Roos F, Mcdermott R, Oyama M, Yamamoto Y, Tomita Y, Miura Y, Ioritani N, Westgeest H, Kubiatowski T, Bal W, Girones Sarrio R, Rowe J, Prow DM, Senecal F, Hashemi-sadraei N, Cole SW, Kendall SD, Richards DA, Schnadig ID, Gupta M. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2022;23:1133-44. [DOI: 10.1016/s1470-2045(22)00487-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
17 Sendur MAN. Adjuvant immunotherapy for renal cell carcinoma. The Lancet Oncology 2022;23:1110-1. [DOI: 10.1016/s1470-2045(22)00509-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Msaouel P, Lee J, Karam JA, Thall PF. A Causal Framework for Making Individualized Treatment Decisions in Oncology. Cancers (Basel) 2022;14:3923. [PMID: 36010916 DOI: 10.3390/cancers14163923] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Michaelis J, Grabbert M, Sigle A, Yilmaz M, Schlager D, Gratzke C, Miernik A, Schoeb DS. Tyrosine Kinase Inhibitors in the Treatment of Metastasised Renal Cell Carcinoma—Future or the Past? Cancers 2022;14:3777. [DOI: 10.3390/cancers14153777] [Reference Citation Analysis]
20 Roldán FL, Izquierdo L, Ingelmo-torres M, Lozano JJ, Carrasco R, Cuñado A, Reig O, Mengual L, Alcaraz A. Prognostic Gene Expression-Based Signature in Clear-Cell Renal Cell Carcinoma. Cancers 2022;14:3754. [DOI: 10.3390/cancers14153754] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Yin Z, Chen D, Liang S, Li X. . JHC 2022;Volume 9:929-46. [DOI: 10.2147/jhc.s357313] [Reference Citation Analysis]
22 Li Z, Xu H, Yu L, Wang J, Meng Q, Mei H, Cai Z, Chen W, Huang W. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clin Transl Med 2022;12:e970. [PMID: 35802820 DOI: 10.1002/ctm2.970] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Apolo AB, Msaouel P, Niglio S, Simon N, Chandran E, Maskens D, Perez G, Ballman KV, Weinstock C. Evolving Role of Adjuvant Systemic Therapy for Kidney and Urothelial Cancers. Am Soc Clin Oncol Educ Book 2022;42:1-16. [PMID: 35609225 DOI: 10.1200/EDBK_350829] [Reference Citation Analysis]
24 Marchioni M, Amparore D, Magli IA, Bertolo R, Carbonara U, Erdem S, Ingels A, Muselaers CH, Kara O, Mascitti M, Klatte T, Kriegmair M, Pavan N, Roussel E, Pecoraro A, Marandino L, Campi R, Schips L. Potential benefit of lymph node dissection during radical nephrectomy for kidney cancer: A review and critical analysis of current literature. Asian Journal of Urology 2022. [DOI: 10.1016/j.ajur.2022.03.007] [Reference Citation Analysis]
25 Bin Riaz I, Riaz Sipra QUA, Naqvi SAA, He H, Siddiqi R, Islam M, Asghar N, Ikram W, Xu W, Liu H, Singh P, Ho TH, Bilen MA, Zakharia Y, Bryce AH, Murad MH. Quantifying Absolute Benefit for Adjuvant Treatment Options in Renal Cell Carcinoma: A Living Interactive Systematic Review and Network Meta-analysis. Critical Reviews in Oncology/Hematology 2022. [DOI: 10.1016/j.critrevonc.2022.103706] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Khaleel S, Jiang S, Kotecha RR, Hakimi AA. Neoadjuvant Systemic Therapy in Localized and Locally Advanced Renal Cell Carcinoma. Front Urol 2022;2. [DOI: 10.3389/fruro.2022.864778] [Reference Citation Analysis]
27 Cherny NI. An appraisal of FDA approvals for adult solid tumours in 2017-2021: has the eagle landed? Nat Rev Clin Oncol 2022. [PMID: 35484286 DOI: 10.1038/s41571-022-00636-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
28 Serzan M, Atkins MB. Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab. Expert Rev Anticancer Ther 2022. [PMID: 35483033 DOI: 10.1080/14737140.2022.2072300] [Reference Citation Analysis]
29 Kroeger N, Lebacle C, Hein J, Rao PN, Nejati R, Wei S, Burchardt M, Drakaki A, Strother M, Kutikov A, Uzzo R, Pantuck AJ. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma. Eur J Cancer 2022;168:68-76. [PMID: 35461012 DOI: 10.1016/j.ejca.2022.03.023] [Reference Citation Analysis]
30 Lunger L, Amiel T, Gschwend JE. [Aftercare and adjuvant therapy for advanced renal cell carcinoma]. Urologe A 2022. [PMID: 35377013 DOI: 10.1007/s00120-022-01812-9] [Reference Citation Analysis]
31 Yiu W, Chen J, Zhao B, Zhang W, Chen L, Liu H, Tang M. The Efficacy of Adjuvant Targeted Therapy in Patients with Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/7341294] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Cetin B, Wabl CA, Gumusay O. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients. Curr Treat Options Oncol 2022. [PMID: 35316480 DOI: 10.1007/s11864-022-00966-0] [Reference Citation Analysis]
33 Tan WC, Kanesvaran R. Current standards and practice changing studies in genitourinary (GU) cancers-a review of studies in localized/early GU cancers. ESMO Open 2022;7:100432. [PMID: 35272133 DOI: 10.1016/j.esmoop.2022.100432] [Reference Citation Analysis]
34 Oza B, Eisen T, Frangou E, Stewart GD, Bex A, Ritchie AWS, Kaplan R, Smith B, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Joniau S, Hancock B, Hermann GG, Bellmunt J, Parmar MKB, Royston P, Meade A. External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell Cancer. J Clin Oncol 2022;:JCO2101090. [PMID: 35213214 DOI: 10.1200/JCO.21.01090] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 An J, Packiam VT, Chennamadhavuni A, Richards J, Jain J, Mott SL, Garje R. Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma. Front Oncol 2021;11:786307. [PMID: 35083144 DOI: 10.3389/fonc.2021.786307] [Reference Citation Analysis]
36 Saleh K, Kordahi M, Felefly T, Kourie HR, Khalife N. Pembrolizumab: first adjuvant immunotherapy in renal cell carcinoma? Future Oncology. [DOI: 10.2217/fon-2021-1309] [Reference Citation Analysis]
37 Mattila KE, Vainio P, Jaakkola PM. Prognostic Factors for Localized Clear Cell Renal Cell Carcinoma and Their Application in Adjuvant Therapy. Cancers (Basel) 2022;14:239. [PMID: 35008402 DOI: 10.3390/cancers14010239] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
38 Laukhtina E, Quhal F, Mori K, Sari Motlagh R, Rajwa P, Yanagisawa T, Mostafaei H, König F, Aydh A, Pradere B, Enikeev D, Karakiewicz PI, Schmidinger M, Shariat SF. Pembrolizumab outperforms tyrosine kinase inhibitors as adjuvant treatment in patients with high-risk renal cell carcinoma after nephrectomy. Eur Urol Oncol 2022:S2588-9311(21)00223-6. [PMID: 34992006 DOI: 10.1016/j.euo.2021.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Skelton WP, Dahmen A, Chatwal M, Jain RK, Chahoud J, Spiess PE. Clinical Cases Debate: Neoadjuvant Versus Adjuvant Immunotherapy in Localized Renal Cell Carcinoma (RCC). Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers 2022. [DOI: 10.1007/978-3-030-80546-3_15] [Reference Citation Analysis]
40 Javier-desloges J, Derweesh I, Mckay RR. Targeted Therapy for Renal Cell Carcinoma. Urologic Oncology 2022. [DOI: 10.1007/978-3-030-89891-5_13] [Reference Citation Analysis]
41 Rajasekaran T, Chowdhury AR, Kanesvaran R. Renal Cell Carcinoma in Older Adults with Frailty. Frailty in Older Adults with Cancer 2022. [DOI: 10.1007/978-3-030-89162-6_21] [Reference Citation Analysis]
42 Bassanelli M, Borro M, Roberto M, Giannarelli D, Giacinti S, Di Martino S, Ceribelli A, Russo A, Aschelter A, Scarpino S, Montori A, Pescarmona E, Tomao S, Simmaco M, Cognetti F, Milella M, Marchetti P. A 17-Gene Expression Signature for Early Identification of Poor Prognosis in Clear Cell Renal Cell Carcinoma. Cancers (Basel) 2021;14:178. [PMID: 35008342 DOI: 10.3390/cancers14010178] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Zhang X, Su Z, Lv P, Liu Z, Bai S. Functional, oncological outcomes and safety of nephron-sparing surgery versus radical nephrectomy in patients with localised renal cell carcinoma with high anatomical complexity: a retrospective cohort study with propensity score matching method. BMJ Open 2021;11:e051622. [PMID: 34952876 DOI: 10.1136/bmjopen-2021-051622] [Reference Citation Analysis]
44 Rupal A, Jani C, Singh H, Khanna P, Patel D, Perry J, Jain A, Arora S, Elfiky A. Late metastatic recurrence of renal cell carcinoma in the heart and mediastinum: A case report and review of literature. Current Problems in Cancer: Case Reports 2021;4:100119. [DOI: 10.1016/j.cpccr.2021.100119] [Reference Citation Analysis]
45 Anker J, Miller J, Taylor N, Kyprianou N, Tsao CK. From Bench to Bedside: How the Tumor Microenvironment Is Impacting the Future of Immunotherapy for Renal Cell Carcinoma. Cells 2021;10:3231. [PMID: 34831452 DOI: 10.3390/cells10113231] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
46 McAlpine K, Lavallée LT, Breau RH. Evidence-based Urology: Surrogate Endpoints-Con. Eur Urol Focus 2021:S2405-4569(21)00280-7. [PMID: 34702648 DOI: 10.1016/j.euf.2021.10.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Jang A, Adler DM, Rauterkus GP, Bilen MA, Barata PC. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? Cancers (Basel) 2021;13:5065. [PMID: 34680214 DOI: 10.3390/cancers13205065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
48 Guo P, Wang Y, Han Y, Wei D, Zhao J, Li M, Jiang Y, Luo Y. Development and validation of a nomogram to predict postoperative cancer-specific survival of patients with nonmetastatic T3a renal cell carcinoma. Urol Oncol 2021;39:835.e19-27. [PMID: 34620554 DOI: 10.1016/j.urolonc.2021.06.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Zeuschner P, Zaccagnino A, Junker K. [Biomarkers for renal cell tumours]. Aktuelle Urol 2021;52:452-63. [PMID: 34157774 DOI: 10.1055/a-1517-6259] [Reference Citation Analysis]
50 Murphy CC, Fullington HM, Gerber DE, Bowman IA, Puligandla M, Dutcher JP, DiPaola RS, Haas NB. Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG-ACRIN E2805 trial. Cancer Med 2021;10:5917-24. [PMID: 34405965 DOI: 10.1002/cam4.4140] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Doppalapudi SK, Leopold ZR, Thaper A, Kaldany A, Chua K, Patel HV, Srivastava A, Singer EA. Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC. Cancers (Basel) 2021;13:4140. [PMID: 34439293 DOI: 10.3390/cancers13164140] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
52 Volkova MI, Kalinin SA. Does sunitinib still have a place in the current recommendations for the systemic treatment of advanced renal cell carcinoma? Medicinskij sovet 2021. [DOI: 10.21518/2079-701x-2021-9-89-94] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
53 Khan KA, Wu FT, Cruz-Munoz W, Kerbel RS. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer. EMBO Mol Med 2021;13:e08253. [PMID: 34125494 DOI: 10.15252/emmm.201708253] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
54 Sun R, Kong X, Qiu X, Huang C, Wong PP. The Emerging Roles of Pericytes in Modulating Tumor Microenvironment. Front Cell Dev Biol 2021;9:676342. [PMID: 34179005 DOI: 10.3389/fcell.2021.676342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 10.0] [Reference Citation Analysis]
55 Robles JP, Zamora M, Siqueiros-Marquez L, Adan-Castro E, Ramirez-Hernandez G, Nuñez FF, Lopez-Casillas F, Millar RP, Bertsch T, Martínez de la Escalera G, Triebel J, Clapp C. The HGR motif is the antiangiogenic determinant of vasoinhibin: implications for a therapeutic orally active oligopeptide. Angiogenesis 2021. [PMID: 34097181 DOI: 10.1007/s10456-021-09800-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
56 Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer 2021;125:495-509. [PMID: 33911195 DOI: 10.1038/s41416-021-01393-y] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
57 Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clin Cancer Res 2021;27:3397-403. [PMID: 33832947 DOI: 10.1158/1078-0432.CCR-21-0025] [Reference Citation Analysis]
58 Mohammed T, Singh M, Tiu JG, Kim AS. Etiology and management of hypertension in patients with cancer. Cardiooncology 2021;7:14. [PMID: 33823943 DOI: 10.1186/s40959-021-00101-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
59 Zheng W, Zhang S, Guo H, Chen X, Huang Z, Jiang S, Li M. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma. Cell Commun Signal 2021;19:39. [PMID: 33761933 DOI: 10.1186/s12964-021-00728-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
60 Scholtes MP, Alberts AR, Iflé IG, Verhagen PCMS, van der Veldt AAM, Zuiverloon TCM. Biomarker-Oriented Therapy in Bladder and Renal Cancer. Int J Mol Sci 2021;22:2832. [PMID: 33799514 DOI: 10.3390/ijms22062832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
61 Canil C, Kapoor A, Basappa NS, Bjarnason G, Bossé D, Dudani S, Graham J, Gray S, Hansen AR, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Thana M, Winquist E, Wood LA, Reaume MN, Maloni R, Hotte SJ; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Can Urol Assoc J 2021;15:84-97. [PMID: 33830005 DOI: 10.5489/cuaj.7245] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
62 Mollica V, Rizzo A, Di Nunno V, Santoni M, Cheng L, Lopez-Beltran A, Scarpelli M, Cimadamore A, Montironi R, Massari F. Adjuvant therapy in renal cell carcinoma: is it the right strategy to inhibit VEGF? Transl Androl Urol 2021;10:1581-7. [PMID: 33850792 DOI: 10.21037/tau-20-1125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Guo L, Gong H, Tang TL, Zhang BK, Zhang LY, Yan M. Crizotinib and Sunitinib Induce Hepatotoxicity and Mitochondrial Apoptosis in L02 Cells via ROS and Nrf2 Signaling Pathway. Front Pharmacol 2021;12:620934. [PMID: 33597889 DOI: 10.3389/fphar.2021.620934] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
64 Veiga MPPD, Arija IN, García LB, Velarde LC, Espinosa JC. Cáncer renal. Medicine - Programa de Formación Médica Continuada Acreditado 2021;13:1431-1440. [DOI: 10.1016/j.med.2021.02.011] [Reference Citation Analysis]
65 Dumond A, Brachet E, Durivault J, Vial V, Puszko AK, Lepelletier Y, Montemagno C, Pagnuzzi-Boncompagni M, Hermine O, Garbay C, Lagarde N, Montes M, Demange L, Grépin R, Pagès G. Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma. J Exp Clin Cancer Res 2021;40:33. [PMID: 33461580 DOI: 10.1186/s13046-021-01832-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
66 Motzer RJ, Russo P, Haas N, Doehn C, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Lim HY, Melichar B, Zemanova M, Rini B, Choueiri TK, Wood L, Reaume MN, Stenzl A, Chowdhury S, McDermott R, Michael A, Izquierdo M, Aimone P, Zhang H, Sternberg CN; PROTECT study investigators. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334-8. [PMID: 33461782 DOI: 10.1016/j.eururo.2020.12.029] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
67 Simonaggio A, Epaillard N, Pobel C, Moreira M, Oudard S, Vano YA. Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). Cancers (Basel) 2021;13:E231. [PMID: 33435262 DOI: 10.3390/cancers13020231] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
68 Xu C, Wang S, Wu Y, Sun X, Yang D, Wang S. Recent advances in understanding the roles of sialyltransferases in tumor angiogenesis and metastasis. Glycoconj J 2021;38:119-27. [PMID: 33411077 DOI: 10.1007/s10719-020-09967-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
69 Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Smith B, Ritchie AWS, Meade A, Goh J, Gurney H, Harrison M, Fife K, Eisen T, Blinman P, Stockler MR. Individualised Predictions of the Survival Benefit Due to Adjuvant Therapy in a Randomised Trial of Sorafenib after Nephrectomy for Localised Renal Cell Carcinoma. KCA 2020;4:185-95. [DOI: 10.3233/kca-200104] [Reference Citation Analysis]
70 Tacconi EMC, Tuthill M, Protheroe A. Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date. Onco Targets Ther 2020;13:12301-16. [PMID: 33299326 DOI: 10.2147/OTT.S174149] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
71 Kang B, Sun C, Gu H, Yang S, Yuan X, Ji C, Huang Z, Yu X, Duan S, Wang X. T1 Stage Clear Cell Renal Cell Carcinoma: A CT-Based Radiomics Nomogram to Estimate the Risk of Recurrence and Metastasis. Front Oncol 2020;10:579619. [PMID: 33251142 DOI: 10.3389/fonc.2020.579619] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
72 Bensalah K, Bigot P, Albiges L, Bernhard J, Bodin T, Boissier R, Correas J, Gimel P, Hetet J, Long J, Nouhaud F, Ouzaïd I, Rioux-leclercq N, Méjean A. Recommandations françaises du Comité de cancérologie de l’AFU – actualisation 2020–2022 : prise en charge du cancer du rein. Progrès en Urologie 2020;30:S2-S51. [DOI: 10.1016/s1166-7087(20)30749-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
73 Attalla K, Voss MH, Hakimi AA. Prognostic models in papillary renal cell carcinoma. Ann Transl Med 2020;8:1334. [PMID: 33313079 DOI: 10.21037/atm-20-3750] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
74 Eisen T, Frangou E, Oza B, Ritchie AWS, Smith B, Kaplan R, Davis ID, Stockler MR, Albiges L, Escudier B, Larkin J, Bex A, Joniau S, Hancock B, Hermann GG, Bellmunt J, Hodgkinson E, Stewart GD, Barber J, Brown J, McMenemin R, Nathan P, Pickering LM, Parmar MKB, Meade A. Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup Trial. J Clin Oncol 2020;38:4064-75. [PMID: 33052759 DOI: 10.1200/JCO.20.01800] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 17.5] [Reference Citation Analysis]
75 Patel A, Ravaud A, Motzer RJ, Pantuck AJ, Staehler M, Escudier B, Martini JF, Lechuga M, Lin X, George DJ. Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting. Future Oncol 2021;17:403-9. [PMID: 33028084 DOI: 10.2217/fon-2020-0652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Silva Paiva R, Gomes I, Casimiro S, Fernandes I, Costa L. c-Met expression in renal cell carcinoma with bone metastases. J Bone Oncol 2020;25:100315. [PMID: 33024658 DOI: 10.1016/j.jbo.2020.100315] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
77 Wang L, Li Y, Lyu Y, Wen H, Feng C. Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. Cancer Cell Int 2020;20:482. [PMID: 33041663 DOI: 10.1186/s12935-020-01585-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Buchler T. VENUSS rising for papillary renal cell carcinoma prognostication? Ann Transl Med 2020;8:1036. [PMID: 32953836 DOI: 10.21037/atm.2020.03.216] [Reference Citation Analysis]
79 Yuasa T. A novel classification for local recurrence after surgical removal of renal cell cancer. Ann Transl Med 2020;8:970. [PMID: 32953770 DOI: 10.21037/atm.2020.03.199] [Reference Citation Analysis]
80 Ohsugi H, Yoshida T, Ohe C, Ikeda J, Sugi M, Kinoshita H, Tsuta K, Matsuda T. The SSPN Score, a Novel Scoring System Incorporating PBRM1 Expression, Predicts Postoperative Recurrence for Patients with Non-metastatic Clear Cell Renal Cell Carcinoma. Ann Surg Oncol 2021;28:2359-66. [PMID: 32940805 DOI: 10.1245/s10434-020-09075-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
81 Nagl L, Horvath L, Pircher A, Wolf D. Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future Perspectives. Front Cell Dev Biol 2020;8:766. [PMID: 32974337 DOI: 10.3389/fcell.2020.00766] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 22.0] [Reference Citation Analysis]
82 Cortellini A, Buti S, Bersanelli M, Cannita K, Pinterpe G, Venditti O, Verna L, Porzio G, Natoli C, Tinari N, Cindolo L, Di Clemente L, Grassadonia A, De Tursi M, Ficorella C. Predictive Ability for Disease-Free Survival of the GRade, Age, Nodes, and Tumor (GRANT) Score in Patients with Resected Renal Cell Carcinoma. Curr Urol 2020;14:98-104. [PMID: 32774235 DOI: 10.1159/000499252] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
83 Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther 2020;5:137. [PMID: 32728057 DOI: 10.1038/s41392-020-0199-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 52] [Article Influence: 24.0] [Reference Citation Analysis]
84 Peng C, Gu L, Yang L, Wang B, Huang Q, Shen D, Du S, Zhang X, Ma X. Surgical Strategy for the Management of Renal Cell Carcinoma with Inferior Vena Cava Tumor Thrombus. Evolving Trends in Kidney Cancer 2020. [DOI: 10.5772/intechopen.73294] [Reference Citation Analysis]
85 Hassan F, Lambe S, Sharma K, Kapoor A. Current Role of Adjuvant Therapy in High Risk for Recurrence Resected Kidney Cancer. Evolving Trends in Kidney Cancer 2020. [DOI: 10.5772/intechopen.78684] [Reference Citation Analysis]
86 Turner J, Simoes A, Edwards A, Raman R. Medical Management of Renal Cell Cancer. Evolving Trends in Kidney Cancer 2020. [DOI: 10.5772/intechopen.85931] [Reference Citation Analysis]
87 Montemagno C, Pagès G. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Front Cell Dev Biol 2020;8:584. [PMID: 32775327 DOI: 10.3389/fcell.2020.00584] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 9.5] [Reference Citation Analysis]
88 Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol 2020;16:435-51. [PMID: 32561872 DOI: 10.1038/s41581-020-0301-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 23.0] [Reference Citation Analysis]
89 Ouzaid I, Kammerer-Jacquet SF, Khene Z, Ravaud A, Patard JJ, Bensalah K, Rioux-Leclercq N. Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients. Front Surg 2020;7:26. [PMID: 32582758 DOI: 10.3389/fsurg.2020.00026] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
90 Patel HV, Srivastava A, Singer EA. To Be or "Node" to Be: Nodal Disease and the Role of Lymphadenectomy in the Treatment of Renal Cell Carcinoma. Med Res Arch 2020;8:2091. [PMID: 32582841 DOI: 10.18103/mra.v8i5.2091] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. Advancing the Science and Management of Renal Cell Carcinoma: Bridging the Divide between Academic and Community Practices. J Clin Med 2020;9:E1508. [PMID: 32429554 DOI: 10.3390/jcm9051508] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
92 Feng F, Zhang Z, Ding G, Hui L, Li Y, Li H. Personalized anti-cancer drug combination prediction by an Integrated Multi-level Network.. [DOI: 10.1101/2020.05.12.092239] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
93 Hampsch RA, Wells JD, Traphagen NA, McCleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Goen AE, Kinlaw WB, Miller TW. AMPK Activation by Metformin Promotes Survival of Dormant ER+ Breast Cancer Cells. Clin Cancer Res 2020;26:3707-19. [PMID: 32321715 DOI: 10.1158/1078-0432.CCR-20-0269] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 14.5] [Reference Citation Analysis]
94 Han J, Li Q, Li P, Wang S, Zhang R, Qiao Y, Song Q, Fu Z. Reassessment of American Joint Committee on Cancer Staging for Stage III Renal Cell Carcinoma With Nodal Involvement: Propensity Score Matched Analyses of a Large Population-Based Study. Front Oncol 2020;10:365. [PMID: 32266145 DOI: 10.3389/fonc.2020.00365] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
95 Yamazaki H, Tanaka T, Mie K, Nishida H, Miura N, Akiyoshi H. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs. J Vet Intern Med 2020;34:1272-81. [PMID: 32267594 DOI: 10.1111/jvim.15768] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
96 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 8.5] [Reference Citation Analysis]
97 Krege S. [Why have tyrosine kinase inhibitors failed in the adjuvant situation and do checkpoint inhibitors make more sense?]. Urologe A 2020;59:149-54. [PMID: 32076796 DOI: 10.1007/s00120-020-01142-8] [Reference Citation Analysis]
98 Xu W, Atkins MB, McDermott DF. Checkpoint inhibitor immunotherapy in kidney cancer. Nat Rev Urol 2020;17:137-50. [PMID: 32020040 DOI: 10.1038/s41585-020-0282-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 100] [Article Influence: 48.0] [Reference Citation Analysis]
99 Finelli A, Coakley N, Chin J, Flood TA, Loblaw A, Morash C, Shayegan B, Siemens R. Complex surgery and perioperative systemic therapy for genitourinary cancer of the retroperitoneum. Curr Oncol 2020;27:e34-42. [PMID: 32218666 DOI: 10.3747/co.27.5713] [Reference Citation Analysis]
100 Hampsch RA, Wells JD, Traphagen NA, Mccleery CF, Fields JL, Shee K, Dillon LM, Pooler DB, Lewis LD, Demidenko E, Huang YH, Marotti JD, Kinlaw WB, Miller TW. AMPK activation by metformin promotes survival of dormant ER+ breast cancer cells.. [DOI: 10.1101/2020.01.21.914382] [Reference Citation Analysis]
101 Laganosky D, Filson CP, Patil D, Master VA. Survival benefit with extended lymphadenectomy for advanced renal malignancy: A population-based analysis. Asian J Urol 2020;7:29-36. [PMID: 31970069 DOI: 10.1016/j.ajur.2019.06.004] [Reference Citation Analysis]
102 Wei W, Peng R, Kuang L, Xu C, Cao Y, Zeng L, Wen X, Qin Q, Zheng C, Li W, Xia S. Evaluation of immunotherapy and targeted therapy treatment on renal cell carcinoma: A Bayesian network analysis. Oncol Lett 2020;19:261-70. [PMID: 31897138 DOI: 10.3892/ol.2019.11094] [Reference Citation Analysis]
103 Jung N, Mayet W, Mertens P, Meyer (federführend) J, Müller O, Pfeifer M, Schellinger P, Weiss N, Wendtner C. ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE. Rationelle Diagnostik und Therapie in der Inneren Medizin 2020. [DOI: 10.1016/b978-3-437-06282-7.50009-7] [Reference Citation Analysis]
104 Gasch C, Hohenfellner M. Operative Therapie des Nierenzellkarzinoms. Onko-Nephrologie 2020. [DOI: 10.1007/978-3-662-59911-2_14] [Reference Citation Analysis]
105 Agrawal S, Haas NB, Bagheri M, Lane BR, Coleman J, Hammers H, Bratslavsky G, Chauhan C, Kim L, Krishnasamy VP, Marko J, Maher VE, Ibrahim A, Cross F Jr, Liu K, Beaver JA, Pazdur R, Blumenthal GM, Singh H, Plimack ER, Choueiri TK, Uzzo R, Apolo AB. Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. JAMA Oncol 2020;6:133-41. [PMID: 31750870 DOI: 10.1001/jamaoncol.2019.4117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
106 Delecluse S, Zschäbitz S. Klassifikation und medikamentöse Therapie des Nierenzellkarzinoms. Onko-Nephrologie 2020. [DOI: 10.1007/978-3-662-59911-2_16] [Reference Citation Analysis]
107 Mcnamara MA, Zhang T, Harrison MR, George DJ. Cancer of the Kidney. Abeloff's Clinical Oncology 2020. [DOI: 10.1016/b978-0-323-47674-4.00079-7] [Reference Citation Analysis]
108 Zurita AJ. Renal Cell Carcinoma: Oncologist Point of View. Kidney Cancer 2020. [DOI: 10.1007/978-3-030-28333-9_2] [Reference Citation Analysis]
109 Chen EJ. Systemic Therapies for the Treatment of Renal Cell Carcinoma. Renal Cancer 2020. [DOI: 10.1007/978-3-030-24378-4_23] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
110 Khalili N, Khalili N, Rezaei N. Immunotherapy in Bladder and Renal Cancers. Cancer Immunology 2020. [DOI: 10.1007/978-3-030-57949-4_18] [Reference Citation Analysis]
111 Kanesvaran R, Tan HS. Kidney Cancer in Older Adults. Geriatric Oncology 2020. [DOI: 10.1007/978-3-319-57415-8_24] [Reference Citation Analysis]
112 Parmar A, Bjarnason GA. Individualization of Dose and Schedule Based On Toxicity for Oral VEGF Drugs in Kidney Cancer. KCA 2019;3:213-25. [DOI: 10.3233/kca-190077] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
113 Kuczynski EA, Reynolds AR. Vessel co-option and resistance to anti-angiogenic therapy. Angiogenesis 2020;23:55-74. [PMID: 31865479 DOI: 10.1007/s10456-019-09698-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 15.3] [Reference Citation Analysis]
114 Shao Y, Xiong S, Sun G, Dou W, Hu X, Yang W, Lia T, Deng S, Wei Q, Zeng H, Li X. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma. Cancer Med 2020;9:959-70. [PMID: 31840431 DOI: 10.1002/cam4.2775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
115 Shao N, Su H, Ye D. Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib. Aging (Albany NY) 2019;11:11490-503. [PMID: 31825895 DOI: 10.18632/aging.102549] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
116 Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A. Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial. Ann Oncol 2018;29:2098-104. [PMID: 30412222 DOI: 10.1093/annonc/mdy329] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
117 Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, Byun SS, Lee JL, Master V, Jin J, DeBenedetto R, Linke R, Casey M, Rosbrook B, Lechuga M, Valota O, Grande E, Quinn DI. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol 2018;29:2371-8. [PMID: 30346481 DOI: 10.1093/annonc/mdy454] [Cited by in Crossref: 111] [Cited by in F6Publishing: 124] [Article Influence: 37.0] [Reference Citation Analysis]
118 Vasudev NS, Hutchinson M, Trainor S, Ferguson R, Bhattarai S, Adeyoju A, Cartledge J, Kimuli M, Datta S, Hanbury D, Hrouda D, Oades G, Patel P, Soomro N, Stewart GD, Sullivan M, Webster J, Messenger M, Selby PJ, Banks RE. UK Multicenter Prospective Evaluation of the Leibovich Score in Localized Renal Cell Carcinoma: Performance has Altered Over Time. Urology 2020;136:162-8. [PMID: 31705948 DOI: 10.1016/j.urology.2019.09.044] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
119 Chipollini J, da Costa WH, Werneck da Cunha I, de Almeida E Paula F, Guilherme O Salles P, Azizi M, Spiess PE, Abreu D, Zequi SC. Prognostic value of PD-L1 expression for surgically treated localized renal cell carcinoma: implications for risk stratification and adjuvant therapies. Ther Adv Urol 2019;11:1756287219882600. [PMID: 31662794 DOI: 10.1177/1756287219882600] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
120 Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. J Urol 2020;203:684-9. [PMID: 31596672 DOI: 10.1097/JU.0000000000000588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
121 Yu A, Zlatev DV, Blute ML Sr. Revisiting the role of lymph node dissection in renal cell carcinoma. Ann Transl Med 2019;7:S91. [PMID: 31576299 DOI: 10.21037/atm.2019.04.45] [Reference Citation Analysis]
122 Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Mol Cancer Ther 2020;19:147-56. [PMID: 31582532 DOI: 10.1158/1535-7163.MCT-18-1202] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
123 Klatte T, Gallagher KM, Afferi L, Volpe A, Kroeger N, Ribback S, McNeill A, Riddick ACP, Armitage JN, 'Aho TF, Eisen T, Fife K, Bex A, Pantuck AJ, Stewart GD. The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort. BMC Med 2019;17:182. [PMID: 31578141 DOI: 10.1186/s12916-019-1419-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
124 Hotte SJ, Kapoor A, Basappa NS, Bjarnason G, Canil C, Conter HJ, Czaykowski P, Graham J, Gray S, Heng DYC, Karakiewicz PI, Kollmannsberger C, Lalani AA, North SA, Patenaude F, Soulières D, Violette P, Winquist E, Wood LA, Dudani S, Maloni R, Reaume MN; Kidney Cancer Research Network of Canada. Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Can Urol Assoc J 2019;13:343-54. [PMID: 31603413 DOI: 10.5489/cuaj.6256] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
125 Buller DM, Ristau BT. Improving patient selection for adjuvant therapy in high-risk renal cell carcinoma. Ann Transl Med 2019;7:S104. [PMID: 31576311 DOI: 10.21037/atm.2019.04.75] [Reference Citation Analysis]
126 Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, Briganti A, Montorsi F, Leonardi F, Bandini M. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. Sci Rep 2019;9:13218. [PMID: 31519981 DOI: 10.1038/s41598-019-49250-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
127 de Cássio Zequi S, da Costa WH, Korkes F, Dos Reis RB, Busato WFS, Matheus WE, da Silva Neto DCV, de Almeida E Paula F, Carvalhal GF, Nogueira L, de Carvalho Fernandes R, Silva AGE, Sasse AD, Fay AP, Jardim DL, Bastos DA, da Rosa DAR, Wierman E, Kater F, Schutz FA, Maluf FC, de Oliveira FNG, Morbeck IAP, Rinck JA, da Trindade KM, Maia MC, Souza VC, Monteiro FSM, Soares A. Renal cell cancer treatment: an expert panel recommendation from the Latin American cooperative group-genitourinary and the Latin American renal cancer group: focus on surgery. Ther Adv Urol 2019;11:1756287219872324. [PMID: 31523281 DOI: 10.1177/1756287219872324] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
128 Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clin Cancer Res 2019;25:6098-106. [PMID: 31471309 DOI: 10.1158/1078-0432.CCR-19-0818] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
129 Chen L, Deng W, Liu X, Wang G, Fu B. Impact of pathological T3a upstaging on oncological outcomes of clinical T1 renal cell carcinoma: a meta-analysis. J Cancer 2019;10:4998-5006. [PMID: 31598172 DOI: 10.7150/jca.32859] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
130 Synold TW, Plets M, Tangen CM, Heath EI, Palapattu GS, Mack PC, Stein MN, Meng MV, Lara P, Vogelzang NJ, Thompson IM, Ryan CW. Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249). Kidney Cancer 2019;3:111-8. [PMID: 31763512 DOI: 10.3233/KCA-180049] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
131 Oake JD, Patel P, Lavallée LT, Lattouf JB, Saarela O, Klotz L, Moore RB, Kapoor A, Finelli A, Rendon RA, Kawakami J, So AI, Drachenberg DE. Outcomes and prognosticators of stage 4 renal cell carcinoma with pathological T4 primary lesion using a large, Canadian, multi-institutional database. Can Urol Assoc J 2020;14:24-30. [PMID: 31348746 DOI: 10.5489/cuaj.5941] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
132 Lee CH, Motzer RJ. Kidney cancer in 2016: The evolution of anti-angiogenic therapy for kidney cancer. Nat Rev Nephrol 2017;13:69-70. [PMID: 28100904 DOI: 10.1038/nrneph.2016.194] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
133 White I, Smith S, Rizkalla K, Davies E. Unexpected Gallbladder Metastasis of Clear Cell Renal Carcinoma. Clin Pathol 2019;12:2632010X19861112. [PMID: 31384752 DOI: 10.1177/2632010X19861112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
134 Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. J Clin Oncol 2019;37:2062-71. [PMID: 31216227 DOI: 10.1200/JCO.19.00107] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 16.0] [Reference Citation Analysis]
135 Zeng Y, Yao X, Liu X, He X, Li L, Liu X, Yan Z, Wu J, Fu BM. Anti-angiogenesis triggers exosomes release from endothelial cells to promote tumor vasculogenesis. J Extracell Vesicles 2019;8:1629865. [PMID: 31258881 DOI: 10.1080/20013078.2019.1629865] [Cited by in Crossref: 57] [Cited by in F6Publishing: 54] [Article Influence: 19.0] [Reference Citation Analysis]
136 Assi T, El Rassy E, Farhat F, Kattan J. Overview on the role of preoperative therapy in the management of kidney cancer. Clin Transl Oncol 2020;22:11-20. [PMID: 31144210 DOI: 10.1007/s12094-019-02136-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
137 Vaishampayan U. Personalized approach to systemic therapy of renal cancer. Expert Review of Precision Medicine and Drug Development 2019;4:179-188. [DOI: 10.1080/23808993.2019.1612708] [Reference Citation Analysis]
138 Martini A, Mehrazin R. The potential role of germline single nucleotide polymorphisms for selecting the ideal candidates for sunitinib therapy in patients with locally-advanced renal cell carcinoma. Ann Transl Med 2019;7:S37. [PMID: 31032316 DOI: 10.21037/atm.2019.02.24] [Reference Citation Analysis]
139 Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, Battelli N, Massari F. Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? Ann Transl Med 2019;7:S38. [PMID: 31032317 DOI: 10.21037/atm.2019.02.31] [Reference Citation Analysis]
140 Rühle A, Andratschke N, Siva S, Guckenberger M. Is there a role for stereotactic radiotherapy in the treatment of renal cell carcinoma? Clin Transl Radiat Oncol 2019;18:104-12. [PMID: 31341985 DOI: 10.1016/j.ctro.2019.04.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
141 Patel HD, Puligandla M, Shuch BM, Leibovich BC, Kapoor A, Master VA, Drake CG, Heng DY, Lara PN, Choueiri TK, Maskens D, Singer EA, Eggener SE, Svatek RS, Stadler WM, Cole S, Signoretti S, Gupta RT, Michaelson MD, McDermott DF, Cella D, Wagner LI, Haas NB, Carducci MA, Harshman LC, Allaf ME. The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? Future Oncol 2019;15:1683-95. [PMID: 30968729 DOI: 10.2217/fon-2018-0951] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
142 Ghali F, Patel SH, Derweesh IH. Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma. J Oncol 2019;2019:7309205. [PMID: 31057615 DOI: 10.1155/2019/7309205] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
143 Sha M, Jeong S, Wang X, Tong Y, Cao J, Sun HY, Xia L, Xu N, Xi ZF, Zhang JJ, Kong XN, Xia Q. Tumor-associated lymphangiogenesis predicts unfavorable prognosis of intrahepatic cholangiocarcinoma. BMC Cancer 2019;19:208. [PMID: 30849953 DOI: 10.1186/s12885-019-5420-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
144 Peak TC, Su Y, Chapple AG, Chyr J, Deep G. Syntaxin 6: A novel predictive and prognostic biomarker in papillary renal cell carcinoma. Sci Rep 2019;9:3146. [PMID: 30816681 DOI: 10.1038/s41598-019-39305-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
145 Narayan V, Puligandla M, Haas NB, Subramanian P, DiPaola RS, Uzzo R. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial. J Urol 2019;201:62-8. [PMID: 30130544 DOI: 10.1016/j.juro.2018.08.041] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
146 Spek A, Szabados B, Casuscelli J, Stief C, Staehler M. Adjuvant therapy in renal cell carcinoma: the perspective of urologists. Int J Clin Oncol 2019;24:694-7. [PMID: 30758764 DOI: 10.1007/s10147-019-01398-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Giuliano S, Dufies M, Ndiaye PD, Viotti J, Borchiellini D, Parola J, Vial V, Cormerais Y, Ohanna M, Imbert V, Chamorey E, Rioux-Leclercq N, Savina A, Ferrero JM, Mograbi B, Pagès G. Resistance to lysosomotropic drugs used to treat kidney and breast cancers involves autophagy and inflammation and converges in inducing CXCL5. Theranostics 2019;9:1181-99. [PMID: 30867824 DOI: 10.7150/thno.29093] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
148 Mamtani R, Wang XV, Gyawali B, DiPaola RS, Epperson CN, Haas NB, Dutcher JP. Association between age and sex and mortality after adjuvant therapy for renal cancer. Cancer 2019;125:1637-44. [PMID: 30620389 DOI: 10.1002/cncr.31955] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
149 Chappell JC, Payne LB, Rathmell WK. Hypoxia, angiogenesis, and metabolism in the hereditary kidney cancers. J Clin Invest 2019;129:442-51. [PMID: 30614813 DOI: 10.1172/JCI120855] [Cited by in Crossref: 44] [Cited by in F6Publishing: 49] [Article Influence: 14.7] [Reference Citation Analysis]
150 Schoon JJ, Wood SL, Brown JE. TKIs in Renal Cell Carcinoma. Oncogenomics 2019. [DOI: 10.1016/b978-0-12-811785-9.00039-9] [Reference Citation Analysis]
151 Liu JL, Allaf ME, Gorin MA. Adjuvant Therapy for High-Risk Renal Cell Carcinoma. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_15] [Reference Citation Analysis]
152 Delphine B, Damien A, Philippe B. Renal Cell Carcinoma with Sarcomatoid Features. Rare Kidney Tumors 2019. [DOI: 10.1007/978-3-319-96989-3_9] [Reference Citation Analysis]
153 Bhindi B, Leibovich BC. Approach to the Management of Large and Advanced Renal Tumors. Diagnosis and Surgical Management of Renal Tumors 2019. [DOI: 10.1007/978-3-319-92309-3_9] [Reference Citation Analysis]
154 de Oliveira ACF, de Oliveira FNG. Kidney Cancer: From Basics to Immunotherapy. International Manual of Oncology Practice 2019. [DOI: 10.1007/978-3-030-16245-0_27] [Reference Citation Analysis]
155 Grünwald V, Hornig M. Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. Urologic Oncology 2019. [DOI: 10.1007/978-3-319-42623-5_64] [Reference Citation Analysis]
156 Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of Placebo Adverse Events in Randomized Clinical Trials of Targeted and Immunotherapy Cancer Drugs in the Adjuvant Setting: A Systematic Review and Meta-analysis. JAMA Netw Open 2018;1:e185617. [PMID: 30646278 DOI: 10.1001/jamanetworkopen.2018.5617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
157 Wu FTH, Xu P, Chow A, Man S, Krüger J, Khan KA, Paez-Ribes M, Pham E, Kerbel RS. Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease. Br J Cancer 2019;120:196-206. [PMID: 30498230 DOI: 10.1038/s41416-018-0297-1] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
158 Fonsato V, De Lena M, Tritta S, Brossa A, Calvetti R, Tetta C, Camussi G, Bussolati B. Human liver stem cell-derived extracellular vesicles enhance cancer stem cell sensitivity to tyrosine kinase inhibitors through Akt/mTOR/PTEN combined modulation. Oncotarget 2018;9:36151-65. [PMID: 30546834 DOI: 10.18632/oncotarget.26319] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
159 Sharma T, Tajzler C, Kapoor A. Is there a role for adjuvant therapy after surgery in "high risk for recurrence" kidney cancer? An update on current concepts. Curr Oncol 2018;25:e444-53. [PMID: 30464696 DOI: 10.3747/co.25.3865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
160 Wiechno P, Kucharz J, Sadowska M, Michalski W, Sikora-Kupis B, Jonska-Gmyrek J, Poniatowska G, Nietupski K, Ossolinski K, Demkow T. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol 2018;35:156. [PMID: 30368624 DOI: 10.1007/s12032-018-1217-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
161 Bai ZG, Zhang ZT. A systematic review and meta-analysis on the effect of angiogenesis blockade for the treatment of gastric cancer. Onco Targets Ther 2018;11:7077-87. [PMID: 30410364 DOI: 10.2147/OTT.S169484] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
162 Shao N, Wang HK, Zhu Y, Ye DW. Modification of American Joint Committee on cancer prognostic groups for renal cell carcinoma. Cancer Med 2018;7:5431-8. [PMID: 30306741 DOI: 10.1002/cam4.1790] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
163 Prasad V, Lindner S. Why is research in early-stage cancer research so low? Journal of Cancer Policy 2018;17:4-8. [DOI: 10.1016/j.jcpo.2018.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
164 Lawrence NJ, Martin A, Davis ID, Troon S, Sengupta S, Hovey E, Coskinas X, Kaplan R, Smith B, Ritchie A, Meade A, Eisen T, Blinman P, Stockler MR. What Survival Benefits are Needed to Make Adjuvant Sorafenib Worthwhile After Resection of Intermediate- or High-Risk Renal Cell Carcinoma? Clinical Investigators' Preferences in the SORCE Trial. Kidney Cancer 2018;2:123-31. [PMID: 30740581 DOI: 10.3233/KCA-180038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
165 Kim W, Parikh M, Ryan C, Lara P. Reconciling the Role of Vascular Endothelial Growth Factor-Targeted Therapies in Adjuvant Renal Cell Carcinoma Treatment. KCA 2018;2:95-102. [DOI: 10.3233/kca-180034] [Reference Citation Analysis]
166 Zhang Y, Li D, Jiang Q, Cao S, Sun H, Chai Y, Li X, Ren T, Yang R, Feng F, Li BA, Zhao Q. Novel ADAM-17 inhibitor ZLDI-8 enhances the in vitro and in vivo chemotherapeutic effects of Sorafenib on hepatocellular carcinoma cells. Cell Death Dis 2018;9:743. [PMID: 29970890 DOI: 10.1038/s41419-018-0804-6] [Cited by in Crossref: 55] [Cited by in F6Publishing: 69] [Article Influence: 13.8] [Reference Citation Analysis]
167 Cochin V, Gross-goupil M, Ravaud A. Quelle place pour les traitements médicaux avant et après chirurgie es stades localisés ? Oncol 2018;20:204-210. [DOI: 10.3166/onco-2019-0024] [Reference Citation Analysis]
168 Flynn M, Pickering L, Larkin J, Turajlic S. Immune-checkpoint inhibitors in melanoma and kidney cancer: from sequencing to rational selection. Ther Adv Med Oncol 2018;10:1758835918777427. [PMID: 29977349 DOI: 10.1177/1758835918777427] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
169 Lebacle C, Pooli A, Bessede T, Irani J, Pantuck AJ, Drakaki A. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol 2019;37:115-23. [PMID: 29858701 DOI: 10.1007/s00345-018-2355-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
170 Pinter M, Jain RK. Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med 2017;9:eaan5616. [PMID: 28978752 DOI: 10.1126/scitranslmed.aan5616] [Cited by in Crossref: 152] [Cited by in F6Publishing: 160] [Article Influence: 38.0] [Reference Citation Analysis]
171 Sun M, Marconi L, Eisen T, Escudier B, Giles RH, Haas NB, Harshman LC, Quinn DI, Larkin J, Pal SK, Powles T, Ryan CW, Sternberg CN, Uzzo R, Choueiri TK, Bex A. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. Eur Urol 2018;74:611-20. [PMID: 29784193 DOI: 10.1016/j.eururo.2018.05.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 14.5] [Reference Citation Analysis]
172 Klatte T, Rossi SH, Stewart GD. Prognostic factors and prognostic models for renal cell carcinoma: a literature review. World J Urol 2018;36:1943-52. [PMID: 29713755 DOI: 10.1007/s00345-018-2309-4] [Cited by in Crossref: 81] [Cited by in F6Publishing: 73] [Article Influence: 20.3] [Reference Citation Analysis]
173 Ghatalia P, Rathmell WK. Systematic Review: ClearCode 34 - A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC). Kidney Cancer 2018;2:23-9. [PMID: 30320241 DOI: 10.3233/KCA-170021] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
174 Carretero-gonzález A, de Velasco G. Adjuvant Sunitinib for Renal Cell Carcinoma: Still at the Beginning of the Road. KCA 2018;2:1-3. [DOI: 10.3233/kca-170024] [Reference Citation Analysis]
175 Vaishampayan U. Landmark Trials in Renal Cancer. KCA 2018;2:11-21. [DOI: 10.3233/kca-170026] [Reference Citation Analysis]
176 Chandrasekar T, Klaassen Z, Goldberg H, Sayyid RK, Kulkarni GS, Fleshner NE. High competing risks minimize real-world utility of adjuvant targeted therapy in renal cell carcinoma: a population-based analysis. Oncotarget 2018;9:16731-43. [PMID: 29682181 DOI: 10.18632/oncotarget.24675] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
177 Zibelman M, Plimack ER. Integrating Immunotherapy Into the Management of Renal Cell Carcinoma. J Natl Compr Canc Netw 2017;15:841-7. [PMID: 28596263 DOI: 10.6004/jnccn.2017.0103] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
178 Wang X, Hao B, Xu C, Zhao X, Liu C, Chu X, Lv Y, Zhao Y, Zhang S, Wang P, Wang Y. Involvement of erbB4 and tumor marker genes in renal carcinoma regulatory network. Saudi J Biol Sci 2017;24:1787-91. [PMID: 29551924 DOI: 10.1016/j.sjbs.2017.11.013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Ma S, Pradeep S, Hu W, Zhang D, Coleman R, Sood A. The role of tumor microenvironment in resistance to anti-angiogenic therapy. F1000Res 2018;7:326. [PMID: 29560266 DOI: 10.12688/f1000research.11771.1] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 8.5] [Reference Citation Analysis]
180 Sonbol MB, Firwana B, Hilal T, Wang Z, Almader-Douglas D, Joseph RW, Ho TH. Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis. Eur Urol Oncol 2018;1:101-8. [PMID: 30345423 DOI: 10.1016/j.euo.2018.03.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
181 Estabrook R, Cella D, Zhao F, Manola J, DiPaola RS, Wagner LI, Haas NB. Longitudinal and dynamic measurement invariance of the FACIT-Fatigue scale: an application of the measurement model of derivatives to ECOG-ACRIN study E2805. Qual Life Res 2018;27:1589-97. [PMID: 29508208 DOI: 10.1007/s11136-018-1817-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
182 Buti S, Puligandla M, Bersanelli M, DiPaola RS, Manola J, Taguchi S, Haas NB. Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population. Ann Oncol 2017;28:2747-53. [PMID: 28945839 DOI: 10.1093/annonc/mdx492] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
183 Karakiewicz PI, Zaffuto E, Kapoor A, Basappa NS, Bjarnason GA, Blais N, Breau RH, Canil C, Drachenberg D, Hotte SJ, Jeldres C, Jewett MAS, Kassouf W, Kollmannsberger C, Lavallée LT, Maloni R, Patenaude F, Pouliot F, Reaume MN, Sabbagh R, Shayegan B, So A, Soulières D, Tanguay S, Wood L, Bandini M. Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the literature and meta-analysis of randomized controlled trials. Can Urol Assoc J 2018;12:173-80. [PMID: 29877179 DOI: 10.5489/cuaj.5187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
184 Mathias J, Rini B. Renal Cell Carcinoma. The American Cancer Society's Oncology in Practice 2018. [DOI: 10.1002/9781118592168.ch17] [Reference Citation Analysis]
185 Liu B, Ding F, Liu Y, Xiong G, Lin T, He D, Zhang Y, Zhang D, Wei G. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients. Oncotarget 2016;7:67661-73. [PMID: 27602778 DOI: 10.18632/oncotarget.11813] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 7.5] [Reference Citation Analysis]
186 Doehn C, Grünwald V, Steiner T, Follmann M, Rexer H, Krege S. The Diagnosis, Treatment, and Follow-up of Renal Cell Carcinoma. Dtsch Arztebl Int 2016;113:590-6. [PMID: 27658472 DOI: 10.3238/arztebl.2016.0590] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
187 Graff J, Severin K, Jamitzky T, Rohde D. Aktuelle Aspekte zur Therapie des Nierenzellkarzinoms. best practice onkologie 2018;13:8-17. [DOI: 10.1007/s11654-017-0064-4] [Reference Citation Analysis]
188 Capogrosso P, Larcher A, Sjoberg DD, Vertosick EA, Cianflone F, Dell'Oglio P, Carenzi C, Salonia A, Vickers AJ, Montorsi F, Bertini R, Capitanio U. Risk Based Surveillance after Surgical Treatment of Renal Cell Carcinoma. J Urol 2018;200:61-7. [PMID: 29371091 DOI: 10.1016/j.juro.2018.01.072] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
189 D'Amico L, Belisario D, Migliardi G, Grange C, Bussolati B, D'Amelio P, Perera T, Dalmasso E, Dalle Carbonare L, Godio L, Comoglio P, Trusolino L, Ferracini R, Roato I. C-met inhibition blocks bone metastasis development induced by renal cancer stem cells. Oncotarget 2016;7:45525-37. [PMID: 27322553 DOI: 10.18632/oncotarget.9997] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
190 Vaishampayan U. Evolving Treatment Paradigms in Non-clear Cell Kidney Cancer. Curr Treat Options Oncol 2018;19:5. [PMID: 29368112 DOI: 10.1007/s11864-018-0521-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
191 Ball MW, Srinivasan R. Kidney cancer in 2017: Challenging and refining treatment paradigms. Nat Rev Urol 2018;15:77-8. [PMID: 29335524 DOI: 10.1038/nrurol.2017.220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
192 Sternberg CN, Donskov F, Haas NB, Doehn C, Russo P, Elmeliegy M, Baneyx G, Banerjee H, Aimone P, Motzer RJ. Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. Clin Cancer Res 2018;24:3005-13. [PMID: 29330204 DOI: 10.1158/1078-0432.CCR-17-2652] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
193 Zhang Y, Mai H, Guo G, Bi G, Hao G, Li Y, Wang X, Cheng L, Wang J, Dong R, Liu Z, Chen L, Qu H. Association analysis of SNPs present in plasma with adverse events and population pharmacokinetics in Chinese sunitinib treated patients with renal cell carcinoma. Oncotarget 2018;9:14109-23. [PMID: 29581831 DOI: 10.18632/oncotarget.23881] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
194 Nierenzellkarzinom. Urologische Tumoren 2018. [DOI: 10.1016/b978-3-437-21161-4.00002-x] [Reference Citation Analysis]
195 Lee L, Huned D, Carsen J, Huang H. The incremental benefit of upfront surgery in renal cell carcinoma with venous tumor thrombus of the inferior venae cavae. Urol Sci 2018;29:277. [DOI: 10.4103/uros.uros_31_18] [Reference Citation Analysis]
196 Kanesvaran R, Tan HS. Kidney Cancer in Older Adults. Geriatric Oncology 2018. [DOI: 10.1007/978-3-319-44870-1_24-1] [Reference Citation Analysis]
197 Zhao F, Cella D, Manola J, DiPaola RS, Wagner LI, Haas NSB. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial. Support Care Cancer 2018;26:1889-95. [PMID: 29274030 DOI: 10.1007/s00520-017-4027-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
198 Gill DM, Agarwal N, Vaishampayan U. Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. Am Soc Clin Oncol Educ Book 2017;37:319-29. [PMID: 28561652 DOI: 10.1200/EDBK_174469] [Cited by in Crossref: 6] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
199 Ghatalia P, Koenigsberg R, Pisarcik D, Handorf EA, Geynisman DM, Zibelman M. The Evolution of Clinical Trials in Renal Cell Carcinoma: A Status Report for 2013-2016 from the ClinicalTrials.gov Website. Kidney Cancer 2017;1:151-9. [PMID: 30334017 DOI: 10.3233/KCA-170015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
200 McCormick B, Meissner MA, Karam JA, Wood CG. Surgical Complications of Presurgical Systemic Therapy for Renal Cell Carcinoma: A Systematic Review. Kidney Cancer 2017;1:115-21. [PMID: 30334013 DOI: 10.3233/KCA-170016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
201 Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez JM, Campayo M, Chirivella-González I, García-Del-Muro X, González-Del-Alba A, Grande E, Suárez C. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol 2018;20:47-56. [PMID: 29134564 DOI: 10.1007/s12094-017-1765-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
202 Jilaveanu LB, Puligandla M, Weiss SA, Wang XV, Zito C, Flaherty KT, Boeke M, Neumeister V, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas NB, Kluger HM. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805. Clin Cancer Res 2018;24:217-23. [PMID: 29066509 DOI: 10.1158/1078-0432.CCR-17-1555] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
203 Gu L, Li H, Chen L, Li X, Wang B, Huang Q, Zhang F, Fan Y, Gao Y, Peng C, Ma X, Zhang X. Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study. Transl Oncol 2017;10:949-55. [PMID: 29035731 DOI: 10.1016/j.tranon.2017.09.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
204 Reaume MN, Basappa NS, Wood L, Kapoor A, Bjarnason GA, Blais N, Breau RH, Canil C, Cheung P, Conter HJ, Hotte SJ, Jeldres C, Jewett MAS, Karakiewicz PI, Kollmannsberger C, Patenaude F, So A, Soulières D, Venner P, Violette P, Zalewski P, Chappell H, North SA; Kidney Cancer Research Network of Canada. Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017. Can Urol Assoc J 2017;11:310-20. [PMID: 29382441 DOI: 10.5489/cuaj.4769] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
205 Ho TH, Kapur P, Eckel-Passow JE, Christie A, Joseph RW, Serie DJ, Cheville JC, Thompson RH, Homayoun F, Panwar V, Brugarolas J, Parker AS. Multicenter Validation of Enhancer of Zeste Homolog 2 Expression as an Independent Prognostic Marker in Localized Clear Cell Renal Cell Carcinoma. J Clin Oncol 2017;35:3706-13. [PMID: 28976794 DOI: 10.1200/JCO.2017.73.3238] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
206 Shang J, Xu S, Zhang J, Ran X, Bai L, Tang H. Efficacy of sorafenib in patients with hepatocellular carcinoma after resection: a meta-analysis. Oncotarget 2017;8:109723-31. [PMID: 29312642 DOI: 10.18632/oncotarget.21299] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
207 Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol 2018;73:62-8. [PMID: 28967554 DOI: 10.1016/j.eururo.2017.09.008] [Cited by in Crossref: 102] [Cited by in F6Publishing: 120] [Article Influence: 20.4] [Reference Citation Analysis]
208 Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. JAMA Oncol 2017;3:1249-52. [PMID: 28278333 DOI: 10.1001/jamaoncol.2017.0076] [Cited by in Crossref: 89] [Cited by in F6Publishing: 97] [Article Influence: 17.8] [Reference Citation Analysis]
209 O'Shaughnessy MJ, Murray KS, La Rosa SP, Budhu S, Merghoub T, Somma A, Monette S, Kim K, Corradi RB, Scherz A, Coleman JA. Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. Clin Cancer Res 2018;24:592-9. [PMID: 28954788 DOI: 10.1158/1078-0432.CCR-17-0186] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 11.2] [Reference Citation Analysis]
210 Bellesoeur A, Carton E, Alexandre J, Goldwasser F, Huillard O. Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Des Devel Ther. 2017;11:2801-2811. [PMID: 29033542 DOI: 10.2147/dddt.s109640] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
211 Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopyltsov E, Lee JL, Melichar B, Rini BI, Choueiri TK, Zemanova M, Wood LA, Reaume MN, Stenzl A, Chowdhury S, Lim HY, McDermott R, Michael A, Bao W, Carrasco-Alfonso MJ, Aimone P, Voi M, Doehn C, Russo P, Sternberg CN; PROTECT investigators. Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. J Clin Oncol 2017;35:3916-23. [PMID: 28902533 DOI: 10.1200/JCO.2017.73.5324] [Cited by in Crossref: 218] [Cited by in F6Publishing: 242] [Article Influence: 43.6] [Reference Citation Analysis]
212 Stühler V, Kruck S, Hegemann M, Notohamiprodjo M, Todenhöfer T, Kröger N, Stenzl A, Bedke J. [TKI 2.0 - changes in the medical treatment of renal cell carcinoma]. Urologe A 2018;57:314-22. [PMID: 28879504 DOI: 10.1007/s00120-017-0496-z] [Reference Citation Analysis]
213 Zianne M, Takahashi N, Tsujibata A, Miwa K, Goto Y, Matano Y. Asymptomatic Pancreatic Metastasis from Renal Cell Carcinoma Diagnosed 21 Years after Nephrectomy. Case Rep Gastrointest Med 2017;2017:8765264. [PMID: 28951792 DOI: 10.1155/2017/8765264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
214 Chamie K, Donin NM, Klöpfer P, Bevan P, Fall B, Wilhelm O, Störkel S, Said J, Gambla M, Hawkins RE, Jankilevich G, Kapoor A, Kopyltsov E, Staehler M, Taari K, Wainstein AJA, Pantuck AJ, Belldegrun AS. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol 2017;3:913-20. [PMID: 27787547 DOI: 10.1001/jamaoncol.2016.4419] [Cited by in Crossref: 76] [Cited by in F6Publishing: 84] [Article Influence: 15.2] [Reference Citation Analysis]
215 Flippot R, Mouawad R, Spano JP, Rouprêt M, Compérat E, Bitker MO, Parra J, Vaessen C, Allanic F, Manach Q, Tannir NM, Khayat D, Su X, Malouf GG. Expression of long non-coding RNA MFI2-AS1 is a strong predictor of recurrence in sporadic localized clear-cell renal cell carcinoma. Sci Rep 2017;7:8540. [PMID: 28819235 DOI: 10.1038/s41598-017-08363-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
216 Blick C, Ritchie AWS, Eisen T, Stewart GD. Improving outcomes in high-risk, nonmetastatic renal cancer: new data and ongoing trials. Nat Rev Urol 2017;14:753-9. [PMID: 28762388 DOI: 10.1038/nrurol.2017.123] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
217 Harshman LC, Drake CG, Haas NB, Manola J, Puligandla M, Signoretti S, Cella D, Gupta RT, Bhatt R, Van Allen E, Lara P, Choueiri TK, Kapoor A, Heng DYC, Shuch B, Jewett M, George D, Michaelson D, Carducci MA, McDermott D, Allaf M. Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC-A Possible Path Forward. Kidney Cancer 2017;1:31-40. [PMID: 30334002 DOI: 10.3233/KCA-170010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
218 Ristau BT, Manola J, Haas NB, Heng DYC, Messing EM, Wood CG, Kane CJ, DiPaola RS, Uzzo RG. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial. J Urol. 2018;199:53-59. [PMID: 28728992 DOI: 10.1016/j.juro.2017.07.042] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
219 Rizzo M, Porta C. Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence. Ther Adv Urol 2017;9:195-207. [PMID: 29662544 DOI: 10.1177/1756287217713902] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
220 Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B, Tzannis K, Kontovinis L, Stravodimos K, Papatsoris A, Mitropoulos D, Deliveliotis C, Dimopoulos MA, Constantinides CA. Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation. Oncologist. 2017;22:667-679. [PMID: 28592625 DOI: 10.1634/theoncologist.2016-0435] [Cited by in Crossref: 48] [Cited by in F6Publishing: 53] [Article Influence: 9.6] [Reference Citation Analysis]
221 Lenis AT, Donin NM, Johnson DC, Faiena I, Salmasi A, Drakaki A, Belldegrun A, Pantuck A, Chamie K. Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials. J Urol 2018;199:43-52. [PMID: 28479237 DOI: 10.1016/j.juro.2017.04.092] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
222 Losing AK, Muth JM, Bubik RJ, Kutzke JL, Soefje SA. Renal Cell Carcinoma. PharmacotherapyFirst: A Multimedia Learning Resource 2017. [DOI: 10.21019/pharmacotherapyfirst.rcc_overview] [Reference Citation Analysis]
223 Ball MW, Singer EA, Srinivasan R. Renal cell carcinoma: molecular characterization and evolving treatment paradigms. Curr Opin Oncol 2017;29:201-9. [PMID: 28252459 DOI: 10.1097/CCO.0000000000000364] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
224 Yue Z, Yun-Shan Z, Feng-Xia X. miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. J Renin Angiotensin Aldosterone Syst 2016;17:1470320316663327. [PMID: 28304186 DOI: 10.1177/1470320316663327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
225 Stellungnahme zur adjuvanten Therapie des fortgeschrittenen Nierenzellkarzinoms. Forum 2017;32:156-156. [DOI: 10.1007/s12312-017-0233-y] [Reference Citation Analysis]
226 Hofer L, Gasch C, Hatiboglu G, Motsch J, Grüllich C, Duensing S, Hohenfellner M. [Level IV inferior vena cava tumor thrombus : A rare diagnosis in patients with renal cell carcinoma]. Urologe A 2017;56:868-75. [PMID: 28349189 DOI: 10.1007/s00120-017-0369-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
227 Gyawali B. Low-value practices in oncology contributing to financial toxicity. Ecancermedicalscience 2017;11:727. [PMID: 28386297 DOI: 10.3332/ecancer.2017.727] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
228 Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. [PMID: 28276433 DOI: 10.1038/nrdp.2017.9] [Cited by in Crossref: 996] [Cited by in F6Publishing: 1122] [Article Influence: 199.2] [Reference Citation Analysis]
229 Vallard A, Trone JC, Langrand-Escure J, Espenel S, Guy JB, Rancoule C, Xia Y, El Meddeb Hamrouni A, Ben Mrad M, Magné N. The world of targeted therapies in kidney cancers: pitfalls, tips and tricks. Onco Targets Ther 2017;10:1375-80. [PMID: 28424553 DOI: 10.2147/OTT.S127919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
230 Taguchi S, Buti S, Fukuhara H, Otsuka M, Bersanelli M, Morikawa T, Miyazaki H, Nakagawa T, Fujimura T, Kume H, Igawa Y, Homma Y. Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality? PLoS One 2017;12:e0172341. [PMID: 28241027 DOI: 10.1371/journal.pone.0172341] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
231 Mallarkey G, Grothey A. European Society for Medical Oncology Copenhagen update: potential practice-changing findings. Ther Adv Med Oncol 2017;9:4-12. [PMID: 28203293 DOI: 10.1177/1758834016679105] [Reference Citation Analysis]
232 Niedersuess-beke D. Milestones in advanced renal cell carcinoma. memo 2017;10:38-41. [DOI: 10.1007/s12254-017-0321-9] [Reference Citation Analysis]
233 Kopečková K. Sunitib in adjuvant treatment for renal cell carcinoma. Onkologie 2017;11:11-13. [DOI: 10.36290/xon.2017.003] [Reference Citation Analysis]
234 Macek P. The update on treatment surgical management of renal tumors. Onkologie 2017;11:14-18. [DOI: 10.36290/xon.2017.004] [Reference Citation Analysis]
235 Albiges L, Choueiri TK. Renal-cell carcinoma in 2016: Advances in treatment - jostling for pole position. Nat Rev Clin Oncol 2017;14:82-4. [PMID: 28071677 DOI: 10.1038/nrclinonc.2016.224] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
236 Grünwald V, Hornig M. Systemic and Sequential Therapy in Advanced Renal Cell Carcinoma. Urologic Oncology 2017. [DOI: 10.1007/978-3-319-42603-7_64-1] [Reference Citation Analysis]
237 Kondo T. Treatment Overview. Renal Cell Carcinoma 2017. [DOI: 10.1007/978-4-431-55531-5_6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
238 Brewster S, Biers S, Challacombe B, Cresswell J, Sinclair A, Smith D. Advances in urology 2015–2016. Journal of Clinical Urology 2017;10:39-48. [DOI: 10.1177/2051415816681238] [Reference Citation Analysis]
239 Abouassaly R, Bream MJ, Smaldone MC, Kutikov A, Shah ND, Gonzalez CM, Williams SB, Thompson RH, Boorjian SA, Kim SP. National utilization of regional lymph node dissection among patients with kidney cancer and clinical lymphadenopathy undergoing radical nephrectomy. Cancer Treatment and Research Communications 2017;12:14-18. [DOI: 10.1016/j.ctarc.2017.05.001] [Reference Citation Analysis]
240 Batra U, Parikh PM, Prabhash K, Tongaonkar HB, Chibber P, Dabkara D, Deshmukh C, Ghadyalpatil N, Hingmire S, Joshi A, Raghunath SK, Rajappa S, Rajendranath R, Rawal SK, Singh M, Singh R, Somashekhar SP, Sood R; Authors OGS RCC Group (in Alphabetical Order) Coordinating Committee., and Expert Group Members. Oncology Gold Standard™ practical consensus recommendations 2016 for treatment of advanced clear cell renal cell carcinoma. South Asian J Cancer 2016;5:167-75. [PMID: 28032079 DOI: 10.4103/2278-330X.189933] [Reference Citation Analysis]
241 Bridgeman VL, Vermeulen PB, Foo S, Bilecz A, Daley F, Kostaras E, Nathan MR, Wan E, Frentzas S, Schweiger T, Hegedus B, Hoetzenecker K, Renyi-Vamos F, Kuczynski EA, Vasudev NS, Larkin J, Gore M, Dvorak HF, Paku S, Kerbel RS, Dome B, Reynolds AR. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models. J Pathol 2017;241:362-74. [PMID: 27859259 DOI: 10.1002/path.4845] [Cited by in Crossref: 127] [Cited by in F6Publishing: 133] [Article Influence: 21.2] [Reference Citation Analysis]
242 Wu FT, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G, Kerbel RS. Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer. Sci Rep 2016;6:36694. [PMID: 27841282 DOI: 10.1038/srep36694] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
243 Brown C. Targeted therapy: An elusive cancer target. Nature 2016;537:S106-8. [PMID: 27626779 DOI: 10.1038/537S106a] [Cited by in Crossref: 49] [Cited by in F6Publishing: 53] [Article Influence: 8.2] [Reference Citation Analysis]
244 Porta C, Chiellino S. ASSURE vs. S-TRAC: conflicting results of adjuvant treatments for kidney cancer in the era of targeted agents and genomics. Ann Transl Med 2016;4:S14. [PMID: 27867982 DOI: 10.21037/atm.2016.10.45] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
245 Wu FT, Man S, Xu P, Chow A, Paez-Ribes M, Lee CR, Pirie-Shepherd SR, Emmenegger U, Kerbel RS. Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. Cancer Res 2016;76:6988-7000. [PMID: 27651308 DOI: 10.1158/0008-5472.CAN-16-0888] [Cited by in Crossref: 31] [Cited by in F6Publishing: 37] [Article Influence: 5.2] [Reference Citation Analysis]
246 Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol. 2016;3:286-292. [PMID: 29264197 DOI: 10.1016/j.ajur.2016.08.006] [Cited by in Crossref: 74] [Cited by in F6Publishing: 72] [Article Influence: 12.3] [Reference Citation Analysis]
247 Schmid TA, Gore ME. Sunitinib in the treatment of metastatic renal cell carcinoma. Ther Adv Urol 2016;8:348-71. [PMID: 27904651 DOI: 10.1177/1756287216663979] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
248 Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960 [PMID: 27621761 DOI: 10.4254/wjh.v8.i23.957] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
249 Chism DD, Rathmell WK. Kidney cancer: Rest ASSUREd, much can be learned from adjuvant studies in renal cancer. Nat Rev Nephrol 2016;12:317-8. [PMID: 27108841 DOI: 10.1038/nrneph.2016.58] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
250 Stone L. Kidney cancer: No advantage of adjuvant sunitinib or sorafenib. Nat Rev Urol 2016;13:240-1. [PMID: 27030525 DOI: 10.1038/nrurol.2016.63] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]